NCI to Conduct Phase 2 Studies of Cytimmune’s lead nanomedicine, CYT-6091

July 15, 2020, Rockville, MD — Cytimmune has signed a Clinical Trial Agreement with the National Cancer Institute (NCI) to conduct clinical studies to include a phase 2 trial of Cytimmune’s lead therapeutic construct, CYT-6091. Clinical studies will be conducted by Dr. Naris Nilubol, an oncologist and surgeon leading the NCI’s endocrine oncology branch. A date has not yet been set to begin these studies.

About Cytimmune

 Cytimmune is a privately held biotechnology company with operations in Rockville, Maryland, and Boston, Massachusetts. The company is a pioneer in nano-engineering, having developed an in vitro, synthetic immune system used for the rapid creation of fully humanized antibodies, and a set of novel technologies designed to improve the targeting, safety, and efficacy of systemically delivered combination cancer therapies. The company’s pipeline of nanomedicines are part of their IO+ platform — a nanoparticle-based delivery system that targets and attacks solid tumor cancers. Cytimmune’s lead product, CYT-6091, which delivers high-dose Tumor Necrosis Factor Alpha, has successfully completed a phase 1 clinical trial at the U.S. National Cancer Institute. 

About the U.S. National Cancer Institute

The U.S. National Cancer Institute coordinates the United States National Cancer Program and is part of the National Institutes of Health, which is one of eleven agencies that are part of the U.S. Department of Health and Human Services.